BioXmark® – Clinical activities:
An investigator initiated clinical trial of BioXmark® is expected to start in Q4 2017. The trial will evaluate the safety and performance of BioXmark® to guide radiotherapy in patients with rectal cancer.
BioXmark® has been evaluated in two investigator initiated clinical trials at the Copenhagen University Hospital (Rigshospitalet).
One trial included 15 patients with locally advanced non-small cell lung cancer (NSCLC) and demonstrated BioXmark® to perform as anticipated when used as a tissue marker to guide radiotherapy. The patients enrolled in the trial have continued in an ongoing follow-up study phase with annual reporting.
Another trial evaluated BioXmark® as a tissue marker to guide radiotherapy of esophageal cancer.